XML 27 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Note 5 - Earnings Per Common Share
3 Months Ended
Sep. 30, 2024
Notes to Financial Statements  
Earnings Per Share [Text Block]

NOTE 5 - EARNINGS PER COMMON SHARE

 

The following table presents the amounts used to compute basic and diluted earnings per common share, as well as the effect of dilutive potential common shares on weighted average shares outstanding:

 

(in thousands, except per share data)

 

Three Months Ended

 
   

September 30

 
   

2024

   

2023

 
BASIC EARNINGS PER SHARE                
                 

Net Income

  $ 6,682     $ 8,028  
                 

Weighted average shares outstanding during the period, net of treasury shares

    28,514       27,738  
                 

Weighted average vested restricted stock units outstanding

    90       82  
                 

Weighted average shares outstanding in the Deferred Compensation Plan during the period

    989       937  

Weighted average shares outstanding

    29,593       28,757  
                 

Basic income per share

  $ 0.23     $ 0.28  
                 

DILUTED EARNINGS PER SHARE

               
                 

Net Income

  $ 6,682     $ 8,028  
                 

Weighted average shares outstanding

               
                 

Basic

    29,593       28,757  
                 

Effect of dilutive securities (a):

               

Impact of common shares to be issued under stock option plans, and Contingently issuable shares, if any

    937       1,198  

Weighted average shares outstanding

    30,530       29,955  
                 

Diluted income per share

  $ 0.22     $ 0.27  
                 

Anti-dilutive securities (b)

    265       -  

 

 

(a)

Calculated using the “Treasury Stock” method as if dilutive securities were exercised and the funds were used to purchase common shares at the average market price during the period.

 

 

(b)

Anti-dilutive securities were excluded from the computation of diluted net income per share for the three months ended September 30, 2024, and September 30, 2023, because the exercise price was greater than the average fair market price of the common shares or because the assumed proceeds from the award’s exercise or vesting was greater than the average fair market price of the common shares.